Camilla Simpson
Vermögen: - $ am 30.06.2026
Vermögen: - $ am 30.06.2026
Camilla V.
Simpson is the founder of Rare Strategic LLC, founded in 2019, serving as President & Managing Member.
Current jobs include Chief Executive Officer at Zehna Therapeutics, Inc. since 2021, Independent Director at Spruce Biosciences, Inc. since 2017, Director at Dyve Biosciences, Inc. since 2020, and Independent Director at GRI Bio, Inc. since 2023.
Former jobs include Director at Aristea Therapeutics, Inc., Director at Vallon Pharmaceuticals, Inc., Senior VP & Head-Product Portfolio Development at BioMarin Pharmaceutical, Inc. from 2017 to 2019, and VP-Regulatory Affairs & Business Development at Shire Pharmaceuticals, Inc. Education includes graduate studies at the University of London, undergraduate studies at Kingston University, and undergraduate studies at National University of Ireland Galway.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.05.2026 | 0 ( -.--% ) | - $ | 30.06.2026 | |
GRI BIO, INC. -.--% | 17.01.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 01.10.2017 |
| GRI BIO, INC. | Direktor/Vorstandsmitglied | 24.04.2023 |
Rare Strategic LLC | Gründer | 01.04.2019 |
Dyve Biosciences, Inc.
Dyve Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Direktor/Vorstandsmitglied | 01.12.2020 |
Zehna Therapeutics, Inc.
Zehna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops non-bactericidal inhibitors for cardiovascular and chronic kidney diseases | Vorstandsvorsitzender | 01.04.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.04.2019 |
| GRI BIOPAR | Direktor/Vorstandsmitglied | - |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat serious inflammatory diseases | Direktor/Vorstandsmitglied | - |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | General Counsel | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 12 |
|---|---|
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kingston University
Kingston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Spruce Biosciences, Inc.
Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
National University of Ireland Galway
National University of Ireland Galway Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat serious inflammatory diseases | Health Technology |
Dyve Biosciences, Inc.
Dyve Biosciences, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Rare Strategic LLC | |
Vallon Pharmaceuticals, Inc.
Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes proprietary biopharmaceutical products | Health Technology |
Zehna Therapeutics, Inc.
Zehna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops non-bactericidal inhibitors for cardiovascular and chronic kidney diseases | Health Technology |
GRI Bio, Inc.
GRI Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of inflammatory, fibrotic and autoimmune diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen